Lipocine Inc. (LPCN) stock
LPCNNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 5, 2026Score 11/3048% below fair value
$1.71+0.09 (+5.56%)
Close on Nov 13, 2026Market cap $14.10MP/E –Yield –
Lipocine operating margin
Operating margin is operating income as a percentage of revenue.
Lipocine's operating margin for the twelve months ending Sep 30, 2026 was -269.1%. For fiscal 2025 it was -524.7%, against -10.3% the year before. The highest annual figure on record is 50.3% in fiscal 2012.
Annual operating margin
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -524.7% | −514.4 |
| FY2024 | Dec 31, 2024 | -10.3% | +2413.6 |
| FY2022 | Dec 31, 2022 | -2423.9% | −2443.4 |
| FY2021 | Dec 31, 2021 | 19.5% | +7838.3 |
| FY2019 | Dec 31, 2019 | -7818.8% | −5172.8 |
| FY2018 | Dec 31, 2018 | -2646.0% | −2696.3 |
| FY2012 | Dec 31, 2012 | 50.3% | – |
Quarterly operating margin
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | -37.9% | +2895.6 |
| Q2 FY2026 | Jun 30, 2026 | -1495.1% | −1109.1 |
| Q1 FY2026 | Mar 31, 2026 | -3224.1% | −997.3 |
| Q4 FY2025 | Dec 31, 2025 | -219.6% | −263.9 |
| Q3 FY2025 | Sep 30, 2025 | -2933.5% | +742.7 |
| Q2 FY2025 | Jun 30, 2025 | -386.0% | −428.3 |
| Q1 FY2025 | Mar 31, 2025 | -2226.8% | −1027.2 |
| Q4 FY2024 | Dec 31, 2024 | 44.3% | +7934.1 |
| Q2 FY2024 | Jun 30, 2024 | -3676.2% | −2970.7 |
| Q1 FY2024 | Mar 31, 2024 | 42.3% | −37.2 |
| Q4 FY2023 | Dec 31, 2023 | -1199.6% | +5226.0 |
| Q1 FY2023 | Mar 31, 2023 | -7889.9% | −6086.3 |
| Q2 FY2022 | Jun 30, 2022 | -705.5% | −89.4 |
| Q4 FY2021 | Dec 31, 2021 | 79.5% | – |
| Q3 FY2021 | Sep 30, 2021 | -6425.6% | – |
| Q3 FY2019 | Sep 30, 2019 | -1803.6% | – |
| Q1 FY2018 | Mar 31, 2018 | -616.1% | – |
See a number that looks wrong?